The feature of Metabolic Syndrome in HIV naive patients is not the same of those 
treated : results from a prospective study by P. Bonfanti et al.
Biomedicine & Pharmacotherapy xxx (2012) xxx–xxx
G Model
BIOPHA-3154; No. of Pages 6Original article
The feature of Metabolic Syndrome in HIV naive patients is not the same of those
treated: Results from a prospective study
Paolo Bonfanti a,*, Giuseppe Vittorio De Socio b, Elena Ricci c, Andrea Antinori d, Canio Martinelli e,
Francesca Vichi f, Giovanni Penco g, Giordano Madeddu h, Giancarlo Oroﬁno i, Laura Valsecchi c,
Stefano Rusconi j, Barbara Menzaghi k, Daria Pocaterra c, Tiziana Quirino k
aDepartment of Infectious Diseases, A. Manzoni Hospital, via dell’Eremo 9, Lecco, Italy
bDepartment of Infectious Diseases, Santa Maria Hospital, Perugia, Italy
cDepartment of Infectious Diseases, Luigi Sacco Hospital, Milano, Italy
dClinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy
eDepartment of Infectious Diseases, Careggi Hospital, Firenze, Italy
fDepartment of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, Italy
gDepartment of Infectious Disease, Galliera Hospital, Genova, Italy
hDepartment of Infectious Diseases, University of Sassari, Sassari, Italy
iDepartment of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy
jClinica Malattie Infettive, University of Milan, Milano, Italy
kDepartment of Infectious Diseases, Busto Arsizio Hospital, Busto Arsizio, Italy
A R T I C L E I N F O
Article history:
Received 4 January 2012






A B S T R A C T
Metabolic Syndrome (MS) is a common disorder combining obesity, dyslipidemia, hypertension, and
insulin resistance. Its prevalence among HIV-infected people is still debated. Besides, how antiretroviral
therapy and HIV infection per se are related to MS is still unclear. All treatment-naı¨ve patients attending
scheduled visits at CISAI group hospitals between January and December 2007 were eligible for the
study. Patients without MS at enrolment were followed-up for 3 years or until they developed MS,
diagnosed according to the National Cholesterol Education Program (NCEP) deﬁnition. The main
objective was to assess the 3-years incidence of MS. MS was evaluated for 188 subjects. Out of them, 62
(33.0%) had started HAART at enrolment, whereas 67 (35.6%) more started during the observation. 59
(31.4%) were still treatment-naive at the study end. MS was newly diagnosed in 14 patients. The
incidence was 2.60 cases/100 person-years (95% CI 1.47–4.51), 2.75 (1.11–5.72) among HAART-naı¨ve
patients and 2.65 (1.23–5.03) in subjects on HAART. Blood pressure did not change in the study period,
whereas in naive patients the HDL level signiﬁcantly lowered (median –6.0 vs. 4.0, P < 0.0001) compared
to HAART-treated patients. Triglicerides increased signiﬁcantly in HAART subjects (median 12.0 vs. 1.0,
P = 0.02), as well as blood glucose (median 6.0 vs. 1.0, P = 0.01). In our population, the overall MS
incidence was low and largely similar in patients who started HAART or remained naive. However, the
feature of MS was different in the two groups, suggesting that in untreated and treated patients MS
developed through different metabolic pathways.
 2012 Elsevier Masson SAS. All rights reserved.
Available online at
www.sciencedirect.com1. Introduction
Metabolic Syndrome (MS) is a common and complex disorder
combining obesity, dyslipidemia, hypertension, and insulin resis-
tance. In the HIV-positive population, MS is considered an
emerging risk factor for overall cardiovascular risk [1–6], though
different populations and ethnic groups show prevalence ranging
from 7 to 45.5% [7]. In the clinical setting, diagnosing MS is useful
to identify and characterize HIV-infected patients at higher* Corresponding author.
E-mail address: bonfanti.paolo@gmail.com (P. Bonfanti).
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0753-3322/$ – see front matter  2012 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.biopha.2012.01.005cardiovascular risk [8]. Nevertheless, how antiretroviral therapy
and HIV infection per se are related to MS is still unclear: to date,
studies have not provided conclusive results [7].
Recently, we have published the results of the cross-sectional
analysis of 292 HAART-naive subjects enrolled in 2007 [9]. Among
them, the prevalence of MS was 12.3%, increasing with age and
lower education. An interesting though not conclusive result was
that treatment-naı¨ve HIV-positive patients in an advanced stage of
the disease had a higher prevalence of abnormal levels of
triglycerides, HDL cholesterol and blood glucose than those at a
less advanced stage. Along the same line, Jacobson et al. [3] found
that MS incidence was higher in patients with 6-months HIV RNAtabolic Syndrome in HIV naive patients is not the same of those
012), doi:10.1016/j.biopha.2012.01.005
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per se was associated to MS.
To add information on the issue, the HERMES project (HIV
Exposure and Risk of MS) was conducted by the CISAI group (Italian
Coordination for Research into Allergy and HIV Infection),
investigating the role of HIV infection and its treatments in the
development of MS. This cohort study only included patients who
were treatment-naı¨ve at entry. A primary objective of this analysis
was to determine the relationship between MS development, HIV
infection and HAART.
2. Methods
Patients were recruited between January 2007 and December
2007. All treatment-naı¨ve patients, attending the visits scheduled at
the start of the study in the CISAI centers, were eligible if they agreed
to enter this observational study. Patients were interviewed by a
physician, and all laboratory tests were performed at the center of
origin, using blood samples taken after 8–12 h fasting. Patients could
start antiretroviral treatment after enrolment if indicated.
All participants gave their informed consent to participate in the
study, which was approved by the institution’s ethics committee.
The following subjects were not eligible: patients who had
started antiretroviral therapy; pregnant women; patients with
ascites; patients aged less than 18; patients unable to sign the
informed consent form.
All centers used a standard data entry form to collect data at
enrolment; main demographic details, as sex, age, ethnicity,
marital status and years of education were recorded.
Medical history included information on previous occurrences
of ischemic heart disease, ictus or transient ischemic attack (TIA),
diabetes, dyslipidemia, malignancies in patient or in his/her ﬁrst
degree relatives.
Dieting and drug treatment for diabetes were recorded.
Information on previously diagnosed hypertension and/or antihy-
pertensive drug treatment use was collected, as well as blood lipid
disorders and related drug treatments. All data were checked with
clinical records where available. Information about treatment
initiation during the follow-up period was also recorded.
Smoking and alcohol consumption were recorded (detailed
description were previously reported [9]) at study entry and end.
Information on co-infection with Hepatitis B or C viruses were
collected, as well as diagnosis of chronic hepatitis and its cause.
The presence of lipodystrophy was also evaluated.
Clinical information regarding HIV infection were collected:
risk factor for HIV acquisition, CDC stage, CD4 + cell count and viral
load at enrolment, nadir CD4 + cell count, years from ﬁrst diagnosis
of HIV infection.
Patients were followed for 3 years or until MS development, if
the diagnose was made before the study end.
2.1. Deﬁnition of Metabolic Syndrome
Blood pressure was measured with the patient in the sitting
position, using a mercury sphygmomanometer and taking the ﬁrst
and ﬁfth Korotkov sounds to indicate systolic and diastolic values,
respectively. Waist circumference was measured with the patient
standing. Plasma triglycerides, HDL cholesterol, total serum choles-
terol, and fasting plasma glucose were measured from a venous blood
sample by a radioenzymatic method. MS was diagnosed according to
the 2003 Adult Treatment Panel (ATP) III criteria [10] (ie, when at
least three of the following alterations were present:
 waist circumference more than102 cm in men and more than
88 cm in women;Please cite this article in press as: Bonfanti P, et al. The feature of Me
treated: Results from a prospective study. Biomed Pharmacother (2 HDL cholesterol level less than 40 mg/dL in men and less than
50 mg/dL in women;
 plasma triglyceride value more than or equal to 150 mg/dL;
 fasting plasma glucose value more than or equal to 110 mg/dL or
use of antidiabetic drugs;
 blood pressure value more than or equal to 130 mm Hg systolic
or more than or equal to 85 mm Hg diastolic).
Regardless of the blood pressure or blood glucose values, use of
antihypertensive or antidiabetic drugs was taken to indicate the
presence of a blood pressure or blood glucose alteration,
respectively.
We also calculated the Global Framingham Risk Score (FRS) as a
better predictor of subclinical atheromatous lesions [11] at entry
and end of the study to compare the variations in treated and
untreated subjects; we calculated two FRSs, including age at study
entry and age at study end. In order to normalize the FRS for
increasing age, at last follow-up we also calculated FRS at last
follow-up considering the actual age (A) and the age at enrolment
(B).
2.2. Statistical analysis
The incidence rate (IR) of MS and the 95% conﬁdence intervals
were calculated as number of new cases per 100 person years, on
the whole sample and in subgroups (gender, age at study entry,
HAART treatment after enrolment). Conﬁdence intervals (CI) at
95% for incidence rates are calculated based on Poisson’s binomial
distribution. Rate ratios (RR) and the 95% CI were calculated, and
logistic regression was used to simultaneously adjust for the
potentially confounding effects of selected variables, according to
the Cox model. Since in terms of exposure to HAART the risk factor
changed over time, patients who started therapy after the
enrolment during the study period were considered in the
HAART-naı¨ve group when still naı¨ve and in the HAART group
thereafter. Patients without MS were considered as the reference
group. Age, sex, and variables that resulted being statistically
signiﬁcant from univariate analysis, were included in the regres-
sion equations. Variables included in the deﬁnition of MS were
excluded from the model. A 95% conﬁdence interval not including
1 along with a P value < 0.05 was taken as the level of statistical
signiﬁcance.
Changes in blood pressure, waist circumference, HDL choles-
terol, triglycerides and blood glucose were calculated as ﬁnal level
minus baseline level. The differences were compared using the
analysis of variance. In order to account for potential confounders,
a general linear model was used, introducing the confounding
variables into the equation. If the variables were not normally
distributed, they were rank-transformed before the multivariate
analysis. Relationships between continuous variables were also
assessed using Pearson’s correlation coefﬁcient, if normally
distributed, or Spearman’s correlation coefﬁcient if not normally
distributed.
Logistic regression was used to evaluate the relation between
MS and several variables assessed at the same time of MS
development or at last visit. We used unconditional multiple
logistic regression, with maximum likelihood ﬁtting, including
terms for age, sex and other potential confounders. Odds ratios
(OR) and the corresponding 95% CI were calculated.
Heterogeneity Chi2 was used to evaluate the relation between
MS criteria and HAART use by drug class (naı¨ve, PI-based and
NNRTI-based therapy). To account for potential confounding, we
used the Cochran-Mantel-Haenszel method; included variables are
listed in the table footnotes.tabolic Syndrome in HIV naive patients is not the same of those
012), doi:10.1016/j.biopha.2012.01.005
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Overall, 292 patients were enrolled. A participating center
withdraw from the study after the enrolment period: 26
patients were not followed any more. Out of 266 remaining
patients, 31 were excluded from the incidence analysis because
they had MS at baseline. Among 235 subjects without MS at
baseline, 195 (83%) were followed-up for 3 years or until MS
was diagnosed. Since seven of them lacked at least one
criterion for MS diagnosis, we could evaluate MS in 188
subjects.The patients lost to follow-up were mainly males aged
less than 50 years (63%).
3.1. Metabolic Syndrome incidence
In the 3-year follow-up period, 14 patients developed MS, three
females and 11 males.Table 1
General characteristics and immunological status of patients evaluated in the HERMES
Variable Total Without MS 
N 188 174 (92.5) 
Age (median, interquartile range) 38 (32–47) 38 (32–45) 
BMI (mean, SD) 23.2 (3.1) 22.9 (2.8) 
Gender (n %)
M 142 (75.5) 131 (75.3) 
Fa 46 (24.5) 43 (24.7) 
Ethnicity (n %)
Caucasian 168 (89.4) 154 (88.5) 
Other 20 (10.6) 20 (11.5) 
Risk factor for HIV acquisition (n %)
IDU 20 (11.4) 18 (11.0) 
Heterosexual intercourses 85 (47.7) 77 (47.0) 
Homo/bi-sexual intercourses 71 (40.3) 68 (41.4) 
Transfusion 1 (0.6) 1 (0.6) 
Physical activity at enrolment (n %)
Yes 58 (30.8) 57 (32.8) 
No 130 (69.2) 117 (67.2) 
CD4 at enrolment (n %)
< 200 34 (18.1) 32 (18.4) 
200–500 93 (49.5) 88 (50.6) 
> 500 61 (32.4) 54 (31.0) 
Log10 HIV RNA at enrolment (n %)
 5.00 41 (22.0) 41 (23.7) 
< 5.00 145 (78.0) 132 (76.3) 
CD4 at last visit (n %)
< 200 10 (5.4) 9 (5.2) 
200–500 83 (44.4) 76 (43.9) 
> 500 94 (50.3) 88 (50.9) 
Logistic 
< 200
Detectable HIV RNA at last visitd (n %)
Yes 21 (16.3) 19 (15.6) 
No 108 (80.6) 103 (84.4) 
Logistic 
Baseline FRS (n %)
< 5.00 110 (58.8) 107 (61.8) 
5.00–10.00 42 (22.5) 38 (22.0) 
 10.00 35 (18.7) 28 (16.2) 
FRS at last follow-up A (actual age) (n %)
< 5.00 90 (51.7) 88 (54.7) 
5.00–10.00 41 (23.6) 38 (23.6) 
 10.00 43 (24.7) 35 (21.7) 
Logistic 
FRS at last follow-up B (baseline age) (n %)
< 5.00 108 (58.4) 105 (61.4) 
5.00–10.00 36 (19.5) 34 (19.9) 
 10.00 41 (22.2) 32 (18.7) 
Logistic 
Positive criteria at baseline (n %)
0 62 (33.0) 62 (35.6) 
1 76 (40.4) 70 (40.2) 
2 50 (36.6) 42 (24.2) 
HAART (n %)
Please cite this article in press as: Bonfanti P, et al. The feature of Me
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4.51), 2.35 (0.60–6.40) in females and 2.80 (1.47–4.86) in males.
Among patients who remained HAART-naı¨ve, the incidence was
2.75 (1.11–5.72), whereas in subjects who started HAART it was
2.65 (1.23–5.03).
Subjects who entered the study less or equal to 50 years old
were less prone to MS: in this group MS incidence was 1.85/100
person-years (0.86–3.51) versus 6.82/100 person-years (2.49–
14.84) in people aged more than 50 years. In percentage, MS
developed in 11.9% of subjects who remained naı¨ve over the
observation period and in 8% of patients who started HAART after
the enrolment visit.
3.2. Patients’ characteristics
The patients’ characteristics and the risk ratios are shown in
Table 1. Gender and risk factor for HIV acquisition were not study by Metabolic Syndrome status.
With MS P RRe 95% CIe Pe Reference
variable
14 (7.5) –
47 (33–53) 0.04 3.4 1.2–11.0 0.03 < 50
27.1 (3.8) 0.001 15.6 3.2–69.6 0.001 < 25
11 (78.6) 0.83 0.9 0.3–3.6 0.98 M
3 (21.4) 1
14 (100) 0.37 – – – Caucasian
0 (0)




1 (7.1) 0.07b 0.4 0.1–2.6 0.08 No
13 (93.9) 1
2 (14.3) 1 < 200
5 (35.7) 0.20c 0.7 0.1–3.5 0.64
7 (50.0) 1.6 0.3–7.9 0.55
0 (0) 0.08b – – – < 5.00
13 (100.0)
1 (7.1) 1
7 (50.0) 0.54c 1.2 0.1–11.5 0.88
6 (42.9) 0.8 0.1–8.0 0.87
(OR)
2 (28.6) 0.32b 3.1 0.7–14.6 0.15 No
5 (71.4) 1
(OR)
3 (21.4) 1 < 5.00
4 (28.6) 0.0007c 1.9 0.4–9.0 0.39
7 (50.0) 7.5 1.8–31.2 0.006
2 (15.4) 1 < 5.00
3 (23.1) 0.0002c 2.9 0.4–21.0 0.28
8 (61.5) 9.3 1.6–53.5 0.001
(OR)
3 (21.4) 1 < 5.00
2 (14.3) 0.001c 1.5 0.2–10.5 0.69
9 (64.3) 8.5 1.8–39.1 0.006
(OR)
0 (0) – – – 2
6 (42.9) 0.001c 0.4 0.1–1.3 0.14
8 (57.2) 1
tabolic Syndrome in HIV naive patients is not the same of those
012), doi:10.1016/j.biopha.2012.01.005
Table 1 (Continued )
Variable Total Without MS With MS P RRe 95% CIe Pe Reference
variable
Started at enrolment 62 (33.0) 57 (32.8) 5 (35.7) 0.4 0.1–1.5 0.19 Naive
Started HAART during the study 67 (35.6) 65 (37.4) 2 (14.3) 0.16b 0.4 0.1–2.1 0.30
Naive 59 (31.4) 52 (29.9) 7 (50.0) 1
HAART (third agent) (n %)
NNRTI 58 (45.0) 56 (45.9) 2 (28.6) 0.46b 0.3 0.1–1.6 0.14 Naive
PI 60 (46.5) 56 (45.9) 4 (57.1) 0.70b 0.7 0.2–2.5 0.65
a Out of six menopausal women, two (33.3) had Metabolic Syndrome, versus one (2.6) out of 40 not menopausal (Fisher’s exact test P = 0.04).
b Fisher exact test.
c Mantel Haenzsel Chi2.
d Only patients on HAART.
e Adjusted for gender, age, BMI, HCV co-infection and physical activity (as appropriate). Sometimes the sums do not add up to 188 because of missing values.
Table 2
Changes from baseline during 3-year follow-up according to HAART.
Total (n = 188) Naive (n = 59) HAART (n = 129) P Pa
Median IQ range Median IQ range Median IQ range
SBP 0.0 –10.0–10.3 0.0 –10.0–10.5 0.0 –10.0–10.0 0.91 0.36
DBP 0.0 –5.0–7.5 0.0 –7.5–8.0 0.0 –5.0–5.0 0.87 0.39
Waist circumference 1.0 –1.7–5.0 0.0 –2.0–4.0 1.0 –1.0–7.0 0.06 0.18
HDL cholesterol 0.0 –9.0–11.0 –6.0 –12.0–0.0 4.0 –5.0–12.0 < 0.0001 < 0.0001
Triglycerides 8.5 –20.0–54.0 1.0 –32.0–24.0 12.0 –15.0–58.0 0.02 0.02
Blood glucose 4.0 –3.0–11.0 1.0 –6.0–8.0 6.0 –2.0–11.0 0.03 0.01
FRS A (actual age) 0.98 –0.10–2.77 1.08 0.06–2.45 0.94 –0.11–2.80 0.95 0.94
FRS B (baseline age) 0.33 –0.45–1.64 0.40 –0.44–1.62 0.31 –0.46–1.65 0.91 0.92
MS criteria N % N % N % P Pa
BP 53 28.2 16 27.1 37 28.7 0.83 0.95
Waist circumference 25 13.3 10 17.0 15 11.6 0.32 0.89
HDL cholesterol 73 38.8 26 44.1 47 36.4 0.31 0.18
Triglycerides 71 37.8 14 23.7 57 44.2 0.007 0.008
Blood glucose 13 6.9 3 5.1 10 7.8 0.50 0.22
Number of positive criteria
0 45 23.9 16 27.1 29 22.5
1 70 37.2 27 45.8 43 33.3
2 59 31.4 9 15.2 50 38.8
3 10 5.3 5 8.5 5 3.9 0.44 0.41
4–5 4 2.1 2 3.4 2 1.6
a Adjusted for gender, age, BMI, HCV co-infection and initial level of variable (as appropriate).
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signiﬁcant determinant for MS development (RR = 3.4, 95% CI 1.2–
11.0, P = 0.02), whereas physical activity seemed protective, but
not signiﬁcantly (RR = 0.4, 95% CI 0.1–2.6, P = 0.08).
Baseline FRS more than or equal to 10 was predictive of MS
development (RR = 7.5, 95% CI 1.8–31.2, P = 0.006); FRS more than
or equal to 10 at last follow-up was also associated to MS (OR).
HAART initiation did not appear signiﬁcantly related to MS
development, though the RR = 0.3 suggested a protective role of
NNRTIs.
During follow-up, the median FRS increase was 0.98; patients
who developed MS had a higher FRS at baseline and were subjected
to a higher median increase (6.0) in comparison to patients
without MS (0.9). This difference also emerged when using the age
at enrolment in the FRS equation (2.6 vs. 0.3) and suggested that
factors other than ageing were responsible of FRS increase.
3.3. Metabolic Syndrome criteria analysis
As a secondary objective, we analyzed the single features of MS
(Table 2) according to HAART initiation. Patients who remained
naı¨ve had baseline frequency of low HDL-C level signiﬁcantly
lower than patients who initiated HAART (22.0% vs. 40.3%,Please cite this article in press as: Bonfanti P, et al. The feature of Me
treated: Results from a prospective study. Biomed Pharmacother (2P < 0.05). The baseline prevalence of other MS features were
similar between groups. At study end (or at MS diagnose) HDL-C
frequency did not differ, whereas TGL > 150 mg/dL were signiﬁ-
cantly more frequent in HAART patients.




negative value a decrease as compared to the baseline value.
HAART was associated to HDL-C: patients that started therapy
during the study period showed a median HDL-C increase
signiﬁcantly higher than patients who remained treatment-naı¨ve.
Baseline CD4 cell count < 200 cells/mm3was also related to HDL-C
change: the lower the baseline CD4 cell count, the higher the HDL-
C increase during the study period. This relation was mediated by
the HAART initiation, being subjects with CD4 cell count less than
200 more likely to start HAART.
HAART duration was directly correlated with several metabolic
changes (data not shown in tables): WC (r = 0.15, P = 0.04), HDL-C
(r = 0.26, P = 0.0003). BG was also correlated (r = 0.11) but not
signiﬁcantly. Conversely, study time while still naı¨vewas inversely
correlated to HDL-C (r = –0.20, P = 0.007), WC (r = –0.22, P = 0.003)
and BG (r = -0.16, P = 0.03).tabolic Syndrome in HIV naive patients is not the same of those
012), doi:10.1016/j.biopha.2012.01.005
Table 3
Changes from baseline during 3-year follow-up according to HAART class.
Naive (n = 59) NNRTI (n = 58) PI (n = 60) P Pe
Median IQ range Median IQ range Median IQ range
SBP 0.0 –10.0–10.5 –3.3 –10.0–7.0 0.0 –6.0–12.5 0.28 0.12
DBP 0.0 –7.5–8.0 0.0 –5.0–5.0 0.5 –5.0–6.5 0.69 0.22
Waist circumference 0.0 –2.0–4.0 1.0 –2.0–5.0 3.0 0.0–9.0 0.0009 0.03a
HDL cholesterol –6.0 –12.0–0.0 6.5 –3.0–12.0 4.0 –5.0–14.0 < 0.0001 < 0.0001b
Triglycerides 1.0 –32.0–24.0 5.5 –16.0–39.0 34.5 –7.5–66.5 0.01 0.001a
Blood glucose 1.0 –6.0–8.0 4.0 –1.0–11.0 7.0 –3.5–13.0 0.05 0.04b
FRS A (actual age) 1.08 0.06–2.45 0.37 –0.43–2.22 1.15 0.38–4.31 0.14 0.16
FRS B (baseline age) 0.40 –0.44–1.62 0.07 –1.08–1.16 0.65 –0.05–1.96 0.12 0.14
MS criteria N % N % N % P Pe
BP 16 27.1 18 31.0 16 26.7 0.85 0.48
Waist circumference 10 17.0 6 10.3 9 15.0 0.57 0.55
HDL cholesterol 26 44.1 16 27.6 24 40.0 0.16 0.04c
Triglycerides 14 23.7 19 32.8 31 51.7 0.005 0.10d
Blood glucose 3 5.1 6 10.3 3 5.0 0.42 0.09
Number of positive criteria 0.79 0.70
0 16 27.1 17 29.3 11 18.3
1 27 45.8 20 34.5 20 33.3
2 9 15.2 19 32.8 25 41.7
3 5 8.5 1 1.7 3 5.0
4–5 2 3.4 1 1.7 1 1.7
a NNRTI and naı¨ve groups were signiﬁcantly different from PI group (P = 0.03 and P = 0.01 respectively).
b NNRTI and PI groups were signiﬁcantly different from naı¨ve group (P < 0.0001 and P = 0.0003 respectively).
c NNRTI group was signiﬁcantly different from naı¨ve group (P = 0.04).
d PI group was signiﬁcantly different from naı¨ve group (P = 0.01).
e Adjusted for gender, age, BMI, HCV co-infection and initial level of variable (as appropriate).
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In Table 3, naı¨ve patients were compared to those who started a
PI-based or NNRTI-based therapy. Concerning the WC and the TGL
changes from baseline, NNRTI treated and naı¨ve patients were
different from PI-treated ones that showed a signiﬁcantly greater
WC and TGL increase. However, compared to naı¨ve patients, NNRTI
treated and PI-treated subjects showed a signiﬁcantly higher HDL-
C and BG increase. In the analysis of MS criteria, low HDL-C
criterion was less frequent in the NNRTI group and TGL criterion
was more frequent in the PI group (both signiﬁcant if compared to
naı¨ve patients).
4. Discussion
The main ﬁndings of this study was the low MS incidence and
the different trend of metabolic changes seen in HAART groups.
Other studies have prospectically followed patients to estimate
MS incidence [3,4,12]. Compared to our results, Wand et al. [4]
found a lower baseline prevalence (8.5% with ATP-III MS deﬁnition
vs. 12.3%) and a higher incidence over a 3-year observation period
(12/100 patient-years vs. 2.6/100 patient-years). Another study [3]
found a incidence of MS (15 cases/100 person-years) similar to
Wand, [4] with a baseline prevalence of 24%, but this study
included both naı¨ve and HAART-treated subjects, thus a direct
comparison with our results was not feasible.
Conversely, Palacios et al. [12] surveyed a sample of naı¨ve
patients starting HAART at enrolment: MS at baseline was 16.6%,
and 25% after 48 weeks. During follow-up, 7/50 patients developed
MS, leading an incidence of 14/100 patients/year. Despite the
similar baseline prevalence, MS incidence in our cohort was lower.
However, our study was performed more recently, when new
drugs were available and the physician alert on MS and obesity was
higher compared to the past. This aspect may partially explain the
low MS incidence observed.Please cite this article in press as: Bonfanti P, et al. The feature of Me
treated: Results from a prospective study. Biomed Pharmacother (2We also focused on the comparison between patients who
started HAART and the group that remained naı¨ve. For each
component of MS there is a complex interaction between HIV,
therapy and central obesity. Some retrospective studies found a
higher prevalence of MS associated with HAART use [3,13–16] and
in particular with PIs, [2,3,14,16] whereas others did not ﬁnd any
association [4,12,17,18]. Some authors suggested that HAART
speciﬁcally affected the triglycerides levels [5,19,20] and the
insuline resistance [13]. Speciﬁc antiretroviral therapies are known
to affect individual components of MS adversely, such as increasing
triglycerides as lopinavir/ritonavir, [21,22] but also efavirenz [23].
Along this line, we found that the most frequent MS feature among
patients starting HAART was TGL > 150 mg/dL; the change from
baseline was signiﬁcantly higher in patients on HAART as
compared to naı¨ve subjects. NNRTI-based regimen seemed
associated to lower TGL increase than PI-based regimens. Among
subjects on PIs, lopinavir/ritonavir-treated patients had blood lipid
levels similar to those on other PIs (data not shown in tables).
In our sample, PIs seemed related to a signiﬁcant WC increase,
as is well documented [24]. Moreover, use of indinavir and
lopinavir/ritonavir has been associated with increasing fasting
glucose [25,26]. In our study, we found a slight median increase of
BG level, as well as a higher incidence of this MS component among
patients on HAART; the former was statistically signiﬁcant.
Comparing PI- and NNRTI-based treatments with naı¨ve patients,
we found that both regimens were associated with a signiﬁcant BG
increase, though this feature did not emerge in the criteria analysis
due to the low number of cases.
On the other hand, some therapies have been associated with
improvements in metabolic proﬁles, such as increases in HDL
cholesterol [27,28]. The association between HIV infection and low
HDL is well established [29,30]. A recent study [31] suggested that
HIV-associated dyslipidemia was, partially at least, related to
chronic inﬂammation, and that the effect of HAART on HDL changes
could be mediated by suppressing inﬂammation. In fact, inﬂamma-
tion induces major changes in HDL levels and composition.tabolic Syndrome in HIV naive patients is not the same of those
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BIOPHA-3154; No. of Pages 6Interestingly, HDL levels and functions are altered in several
immune-mediated disorders, such as rheumatoid arthritis, systemic
lupus eritematosus, Crohn’s disease and multiple sclerosis as well as
during inﬂammatory responses. Changes in HDL levels may
represent a predictable response to attenuation of inﬂammation
[32]. Speciﬁcally, HIV infection and chronic inﬂammation impairs
the ﬁrst step of reverse cholesterol transport, namely cholesterol
efﬂux from macrophages that plays a key role in maintaining cell
cholesterol homeostasis [33].
In our sample, we found a signiﬁcant HDL-C change from
baseline, between naı¨ve and treated patients, that led to a
frequency of the feature higher in the former, though not
signiﬁcantly. In the regimen analysis, the frequency of HDL-C
criteria was signiﬁcantly lower in the NNRTI-based treatment, in
comparison to PI and naı¨ve subjects.
We also investigated the cardiovascular risk factors at baseline
and at follow-up. The estimated cardiovascular risk at baseline and
at the end of follow-up was unchanged comparing naı¨ve and
HAART-treated patients, suggesting that the FRS increase due to
TGL and total cholesterol was possibly balanced by the concomi-
tant HDL-C increase. In the light of this ﬁnding, HAART did not
seem responsible for signiﬁcant additional vascular damage.
The main limitation of this study was the low number of new
MS cases that prevented us from ﬁnding potentially signiﬁcant risk
factors. In some cases, as in the analysis for drugs, the lack of
statistical signiﬁcance may be due to the lack of power.
However, this study has several strength. First of all, we have
had the possibility to compare MS incidence in patients who
started HAART, using the group that remained naı¨ve as compari-
son. Then, we reliably collected information about potential
confounders at baseline. Lastly, the 3-year follow-up period was
adequate for our purpose.
In conclusion, we found a low MS incidence in our population of
HIV-positive subjects, naı¨ve at enrolment. Furthermore, the
incidence of MS was similar in patients who remained naive
and in those who started treatment. However, the features of MS
were different in the two groups: in this sample, TGL and BG
increases were more frequent in HAART-treated (in particular PI-
treated) patients and HDL-C decrease was more frequent in naive
subjects, possibly as an expression of inﬂammatory responses.
These characteristics suggest that, in untreated and treated
patients, MS developed through different metabolic pathways.
Disclosure of interest
The authors declare that they have no conﬂicts of interest
concerning this article.
References
[1] Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes
associated with the metabolic syndrome: a summary of the evidence. Diabetes
Care 2005;28:1769–78.
[2] Jerico` C, Knobel H, Montero M, et al. Metabolic Syndrome among HIV-infected
patients: prevalence, characteristics, and related factors. Diabetes Care
2005;28:132–7.
[3] Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of MS in a cohort of HIV-
infected adults and prevalence relative to the US population. J Acquir Immune
Deﬁc Syndr 2006;43:458–66.
[4] Wand H, Calmy A, Carey DL, et al. INITIO Trial International Coordinating
Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes
mellitus after initiation of antiretroviral therapy in HIV infection. AIDS
2007;21:2445–53.
[5] Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected
patients from an urban. Midwestern US outpatient population. Clin Infect Dis
2007;44:726–34.
[6] Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA. Metabolic
syndrome and sub clinical atherosclerosis in patients infected with HIV. Clin
Infect Dis 2007;44:1368–74.
[7] Worm SW, Lundgren JD. The Metabolic Syndrome in HIV. Best Pract Res Clin
Endocrinol Metab 2011;25:479–86.Please cite this article in press as: Bonfanti P, et al. The feature of Me
treated: Results from a prospective study. Biomed Pharmacother (2[8] De Socio GV, Parruti G, Quirino T, et al. For the CISAI study group. Identifying
HIV patients with an unfavorable cardiovascular risk proﬁle in the clinical
practice: results from the SIMONE study. J Infect 2008;57:33–40.
[9] Bonfanti P, De Socio GVL, Marconi P, et al. Is metabolic syndrome associated to
HIV infection per se? Results from the HERMES study. Curr HIV Res
2010;8(2):165–71.
[10] National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treat-
ment Panel III). Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) ﬁnal report. Circulation 2002;
106: 3143–421.
[11] De Socio GVL, Martinelli C, Ricci E, et al. For the HERMES study group. Relations
between cardiovascular risk estimates and sub clinical atherosclerosis in naive
HIV patients: results from the HERMES Study. Int J STD AIDS 2010;21:267–72.
[12] Palacios R, Santos J, Gonza´lez M, Ruiz J, Ma´rquez M. Incidence prevalence of
the metabolic syndrome in a cohort of naı¨ve HIV-infected patients: prospec-
tive analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS
2007;18:184–7.
[13] Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K. Important
differences in components of the metabolic syndrome between HIV patients
with and without highly active antiretroviral therapy, and healthy controls.
Scand J Infect Dis 2006;38:682–9.
[14] Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-
infected patients receiving highly active antiretroviral therapy using Interna-
tional Diabetes Foundation and Adult Treatment Panel III criteria: associations
with insulin resistance, disturbed body fat compartmentalization, elevated C-
reactive protein, and corrected hypoadiponectinemia. Diab Care
2007;30:113–9.
[15] Falasca K, Ucciferri C, Manzoli L, et al. Metabolic syndrome and cardiovascular
risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Phar-
macol 2007;20:519–27.
[16] Jevtovic DJ, Dragovic G, Salemovic D, Ranin J, Djurkovic-Djakovic O. The
metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Biomed Pharmacother 2009;63:337–42.
[17] Bonfanti P, Giannattasio C, Ricci E, et al. HIV and Metabolic Syndrome: a
comparison with the general population. J Acquir Immune Deﬁc Syndr
2007;45:426–31.
[18] Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of
metabolic syndrome among HIV-Infected and HIV-Uninfected women in the
Women’s Interagency HIV study. J AIDS 2008;48:272–80.
[19] Baum MK, Raﬁe C, Lai S, et al. Coronary heart disease (CHD) risk factors and
metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis
2006;2:173–9.
[20] Hansen BR, Petersen J, Haugaard SB, et al. The prevalence of metabolic
syndrome in Danish patients with HIV infection: the effect of antiretroviral
therapy. HIV Medications 2009;10:378–87.
[21] Fontas E, van Leth F, Sabin CA, et al. Lipid proﬁles in HIV-infected patients
receiving combination antiretroviral therapy: are different antiretroviral
drugs associated with different lipid proﬁles? J Infect Diseases
2004;189:1056–74.
[22] Leon A, Martinez E, Sarasa M, et al. Impact of steady-state lopinavir plasma
levels on plasma lipids and body composition after 24 weeks of lopinavir/
ritonavir-containing therapy free of thymidine analogues. JAntimicr Che-
mother 2007;60:824–30.
[23] van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit
different changes in lipid proﬁles in anti-retroviral therapy-naive patients
infected with HIV-1. PLoS Medicine 2004;1:19.
[24] Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease
inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin
resistance. Lancet 1998;351:1881–3.
[25] Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-
seronegative men. Acquired Immune Deﬁciency Syndrome 2001;15:F11–8.
[26] Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/
ritonavir in HIV-negative men. Acquired Immune Deﬁciency Syndrome
2004;18:641–9.
[27] Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density
lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I
production. Arterioscler Thromb Vasc Biol 2009;29:1336–41.
[28] Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and
risk of cardiovascular disease in persons with HIV-1 infection: exploratory
analyses from the SMART trial. Antiviral Therapy 2008;13:177–87.
[29] Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum
lipids in men. JAMA 2003;289:2978–82.
[30] El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose
and insulin levels: results from a large antiretroviral-naı¨ve cohort. HIV Med
2005;6:114–21.
[31] Baker JV, Neuhaus J, Duprez D, et al. Inﬂammation predicts changes in high-
density lipoprotein particles and apolipoprotein A1 following initiation of
antiretroviral therapy. AIDS 2011;25:2133–42.
[32] Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density
lipoproteins as a player in the immune system. Atherosclerosis 2011. doi:
10.1016/j.atherosclerosis.2011.06.045.
[33] Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N,
et al. Human immunodeﬁciency virus impairs reverse cholesterol transport
from macrophages. PLoS Biol 2006;4:e365.tabolic Syndrome in HIV naive patients is not the same of those
012), doi:10.1016/j.biopha.2012.01.005
